Browse RARA

Summary
SymbolRARA
Nameretinoic acid receptor, alpha
Aliases NR1B1; RAR-alpha; nuclear receptor subfamily 1 group B member 1; nucleophosmin-retinoic acid receptor alpha ......
Chromosomal Location17q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus. Cytoplasm. Note=Nuclear localization depends on ligand binding, phosphorylation and sumoylation. Transloaction to the nucleus in the absence of ligand is dependent on activation of PKC and the downstream MAPK phosphorylation.
Domain PF00104 Ligand-binding domain of nuclear hormone receptor
PF00105 Zinc finger
Function

Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence of ligand, the RXR-RAR heterodimers associate with a multiprotein complex containing transcription corepressors that induce histone acetylation, chromatin condensation and transcriptional suppression. On ligand binding, the corepressors dissociate from the receptors and associate with the coactivators leading to transcriptional activation. RARA plays an essential role in the regulation of retinoic acid-induced germ cell development during spermatogenesis. Has a role in the survival of early spermatocytes at the beginning prophase of meiosis. In Sertoli cells, may promote the survival and development of early meiotic prophase spermatocytes. In concert with RARG, required for skeletal growth, matrix homeostasis and growth plate function (By similarity).

> Gene Ontology
 
Biological Process GO:0001101 response to acid chemical
GO:0001501 skeletal system development
GO:0001654 eye development
GO:0001655 urogenital system development
GO:0001657 ureteric bud development
GO:0001818 negative regulation of cytokine production
GO:0001819 positive regulation of cytokine production
GO:0001822 kidney development
GO:0001823 mesonephros development
GO:0001838 embryonic epithelial tube formation
GO:0001841 neural tube formation
GO:0001843 neural tube closure
GO:0001889 liver development
GO:0002064 epithelial cell development
GO:0002065 columnar/cuboidal epithelial cell differentiation
GO:0002066 columnar/cuboidal epithelial cell development
GO:0002067 glandular epithelial cell differentiation
GO:0002068 glandular epithelial cell development
GO:0002237 response to molecule of bacterial origin
GO:0002263 cell activation involved in immune response
GO:0002285 lymphocyte activation involved in immune response
GO:0002286 T cell activation involved in immune response
GO:0002287 alpha-beta T cell activation involved in immune response
GO:0002292 T cell differentiation involved in immune response
GO:0002293 alpha-beta T cell differentiation involved in immune response
GO:0002294 CD4-positive, alpha-beta T cell differentiation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002521 leukocyte differentiation
GO:0002573 myeloid leukocyte differentiation
GO:0002683 negative regulation of immune system process
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0002761 regulation of myeloid leukocyte differentiation
GO:0002762 negative regulation of myeloid leukocyte differentiation
GO:0002828 regulation of type 2 immune response
GO:0002830 positive regulation of type 2 immune response
GO:0003007 heart morphogenesis
GO:0003148 outflow tract septum morphogenesis
GO:0003151 outflow tract morphogenesis
GO:0003205 cardiac chamber development
GO:0003206 cardiac chamber morphogenesis
GO:0003279 cardiac septum development
GO:0003416 endochondral bone growth
GO:0003417 growth plate cartilage development
GO:0006352 DNA-templated transcription, initiation
GO:0006367 transcription initiation from RNA polymerase II promoter
GO:0006413 translational initiation
GO:0006417 regulation of translation
GO:0006446 regulation of translational initiation
GO:0006909 phagocytosis
GO:0007159 leukocyte cell-cell adhesion
GO:0007272 ensheathment of neurons
GO:0007281 germ cell development
GO:0007283 spermatogenesis
GO:0007423 sensory organ development
GO:0007507 heart development
GO:0007548 sex differentiation
GO:0007565 female pregnancy
GO:0007584 response to nutrient
GO:0008366 axon ensheathment
GO:0008406 gonad development
GO:0008584 male gonad development
GO:0009755 hormone-mediated signaling pathway
GO:0009991 response to extracellular stimulus
GO:0010608 posttranscriptional regulation of gene expression
GO:0010720 positive regulation of cell development
GO:0014020 primary neural tube formation
GO:0014706 striated muscle tissue development
GO:0016331 morphogenesis of embryonic epithelium
GO:0017148 negative regulation of translation
GO:0021537 telencephalon development
GO:0021543 pallium development
GO:0021761 limbic system development
GO:0021766 hippocampus development
GO:0021915 neural tube development
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0022412 cellular process involved in reproduction in multicellular organism
GO:0030098 lymphocyte differentiation
GO:0030099 myeloid cell differentiation
GO:0030217 T cell differentiation
GO:0030522 intracellular receptor signaling pathway
GO:0030850 prostate gland development
GO:0030851 granulocyte differentiation
GO:0030852 regulation of granulocyte differentiation
GO:0030853 negative regulation of granulocyte differentiation
GO:0030900 forebrain development
GO:0031076 embryonic camera-type eye development
GO:0031641 regulation of myelination
GO:0031667 response to nutrient levels
GO:0032355 response to estradiol
GO:0032496 response to lipopolysaccharide
GO:0032526 response to retinoic acid
GO:0032609 interferon-gamma production
GO:0032616 interleukin-13 production
GO:0032633 interleukin-4 production
GO:0032634 interleukin-5 production
GO:0032640 tumor necrosis factor production
GO:0032649 regulation of interferon-gamma production
GO:0032656 regulation of interleukin-13 production
GO:0032673 regulation of interleukin-4 production
GO:0032674 regulation of interleukin-5 production
GO:0032680 regulation of tumor necrosis factor production
GO:0032689 negative regulation of interferon-gamma production
GO:0032720 negative regulation of tumor necrosis factor production
GO:0032736 positive regulation of interleukin-13 production
GO:0032753 positive regulation of interleukin-4 production
GO:0032754 positive regulation of interleukin-5 production
GO:0033189 response to vitamin A
GO:0033273 response to vitamin
GO:0034248 regulation of cellular amide metabolic process
GO:0034249 negative regulation of cellular amide metabolic process
GO:0035051 cardiocyte differentiation
GO:0035148 tube formation
GO:0035239 tube morphogenesis
GO:0035264 multicellular organism growth
GO:0035265 organ growth
GO:0035710 CD4-positive, alpha-beta T cell activation
GO:0042092 type 2 immune response
GO:0042093 T-helper cell differentiation
GO:0042110 T cell activation
GO:0042552 myelination
GO:0042692 muscle cell differentiation
GO:0043010 camera-type eye development
GO:0043277 apoptotic cell clearance
GO:0043367 CD4-positive, alpha-beta T cell differentiation
GO:0043370 regulation of CD4-positive, alpha-beta T cell differentiation
GO:0043372 positive regulation of CD4-positive, alpha-beta T cell differentiation
GO:0043401 steroid hormone mediated signaling pathway
GO:0043627 response to estrogen
GO:0044706 multi-multicellular organism process
GO:0045064 T-helper 2 cell differentiation
GO:0045137 development of primary sexual characteristics
GO:0045165 cell fate commitment
GO:0045471 response to ethanol
GO:0045580 regulation of T cell differentiation
GO:0045582 positive regulation of T cell differentiation
GO:0045619 regulation of lymphocyte differentiation
GO:0045621 positive regulation of lymphocyte differentiation
GO:0045622 regulation of T-helper cell differentiation
GO:0045624 positive regulation of T-helper cell differentiation
GO:0045628 regulation of T-helper 2 cell differentiation
GO:0045630 positive regulation of T-helper 2 cell differentiation
GO:0045637 regulation of myeloid cell differentiation
GO:0045638 negative regulation of myeloid cell differentiation
GO:0045666 positive regulation of neuron differentiation
GO:0045785 positive regulation of cell adhesion
GO:0045787 positive regulation of cell cycle
GO:0045947 negative regulation of translational initiation
GO:0046546 development of primary male sexual characteristics
GO:0046631 alpha-beta T cell activation
GO:0046632 alpha-beta T cell differentiation
GO:0046634 regulation of alpha-beta T cell activation
GO:0046635 positive regulation of alpha-beta T cell activation
GO:0046637 regulation of alpha-beta T cell differentiation
GO:0046638 positive regulation of alpha-beta T cell differentiation
GO:0046661 male sex differentiation
GO:0048167 regulation of synaptic plasticity
GO:0048232 male gamete generation
GO:0048384 retinoic acid receptor signaling pathway
GO:0048545 response to steroid hormone
GO:0048568 embryonic organ development
GO:0048608 reproductive structure development
GO:0048705 skeletal system morphogenesis
GO:0048732 gland development
GO:0048736 appendage development
GO:0048738 cardiac muscle tissue development
GO:0050769 positive regulation of neurogenesis
GO:0050804 modulation of synaptic transmission
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0051098 regulation of binding
GO:0051099 positive regulation of binding
GO:0051146 striated muscle cell differentiation
GO:0051216 cartilage development
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051962 positive regulation of nervous system development
GO:0055007 cardiac muscle cell differentiation
GO:0055012 ventricular cardiac muscle cell differentiation
GO:0060008 Sertoli cell differentiation
GO:0060010 Sertoli cell fate commitment
GO:0060173 limb development
GO:0060324 face development
GO:0060348 bone development
GO:0060349 bone morphogenesis
GO:0060350 endochondral bone morphogenesis
GO:0060351 cartilage development involved in endochondral bone morphogenesis
GO:0060411 cardiac septum morphogenesis
GO:0060438 trachea development
GO:0060534 trachea cartilage development
GO:0060537 muscle tissue development
GO:0060541 respiratory system development
GO:0060562 epithelial tube morphogenesis
GO:0060591 chondroblast differentiation
GO:0060606 tube closure
GO:0061008 hepaticobiliary system development
GO:0061035 regulation of cartilage development
GO:0061037 negative regulation of cartilage development
GO:0061448 connective tissue development
GO:0061458 reproductive system development
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071229 cellular response to acid chemical
GO:0071300 cellular response to retinoic acid
GO:0071383 cellular response to steroid hormone stimulus
GO:0071391 cellular response to estrogen stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0071593 lymphocyte aggregation
GO:0071706 tumor necrosis factor superfamily cytokine production
GO:0072001 renal system development
GO:0072073 kidney epithelium development
GO:0072148 epithelial cell fate commitment
GO:0072163 mesonephric epithelium development
GO:0072164 mesonephric tubule development
GO:0072175 epithelial tube formation
GO:0097305 response to alcohol
GO:0098868 bone growth
GO:1902105 regulation of leukocyte differentiation
GO:1902106 negative regulation of leukocyte differentiation
GO:1902107 positive regulation of leukocyte differentiation
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:1903555 regulation of tumor necrosis factor superfamily cytokine production
GO:1903556 negative regulation of tumor necrosis factor superfamily cytokine production
GO:1903706 regulation of hemopoiesis
GO:1903707 negative regulation of hemopoiesis
GO:1903708 positive regulation of hemopoiesis
GO:2000514 regulation of CD4-positive, alpha-beta T cell activation
GO:2000516 positive regulation of CD4-positive, alpha-beta T cell activation
Molecular Function GO:0000900 translation repressor activity, nucleic acid binding
GO:0001972 retinoic acid binding
GO:0003682 chromatin binding
GO:0003707 steroid hormone receptor activity
GO:0003708 retinoic acid receptor activity
GO:0003713 transcription coactivator activity
GO:0003714 transcription corepressor activity
GO:0003729 mRNA binding
GO:0004879 RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding
GO:0005501 retinoid binding
GO:0008134 transcription factor binding
GO:0008144 drug binding
GO:0019840 isoprenoid binding
GO:0030371 translation repressor activity
GO:0031406 carboxylic acid binding
GO:0031490 chromatin DNA binding
GO:0033293 monocarboxylic acid binding
GO:0042805 actinin binding
GO:0042826 histone deacetylase binding
GO:0043168 anion binding
GO:0043422 protein kinase B binding
GO:0043566 structure-specific DNA binding
GO:0044323 retinoic acid-responsive element binding
GO:0045182 translation regulator activity
GO:0046982 protein heterodimerization activity
GO:0048027 mRNA 5'-UTR binding
GO:0051018 protein kinase A binding
GO:0051393 alpha-actinin binding
GO:0090079 translation regulator activity, nucleic acid binding
GO:0098531 transcription factor activity, direct ligand regulated sequence-specific DNA binding
Cellular Component GO:0000785 chromatin
GO:0000790 nuclear chromatin
GO:0015629 actin cytoskeleton
GO:0030425 dendrite
GO:0043025 neuronal cell body
GO:0044297 cell body
GO:0044454 nuclear chromosome part
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-5619507: Activation of HOX genes during differentiation
R-HSA-5617472: Activation of anterior HOX genes in hindbrain development during early embryogenesis
R-HSA-1266738: Developmental Biology
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-383280: Nuclear Receptor transcription pathway
R-HSA-162582: Signal Transduction
R-HSA-5362517: Signaling by Retinoic Acid
Summary
SymbolRARA
Nameretinoic acid receptor, alpha
Aliases NR1B1; RAR-alpha; nuclear receptor subfamily 1 group B member 1; nucleophosmin-retinoic acid receptor alpha ......
Chromosomal Location17q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RARA and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between RARA and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23770850Acute Promyelocytic Leukemia with PML-RARAInhibit immunity (T cell function)It has been established that impairment of the immunoproteasome subunits, that is, PSMB8, PSMB9 and PSMB10 (PSMBs), is critical for malignant cells to escape immune recognition. Collectively, our data demonstrate that PML/RARĪ± suppresses PU.1-dependent activation of the immunosubunits, which may facilitate the escape of APL cells from immune surveillance in leukemia development, and ATRA treatment is able to reactivate their expression, which would promote more efficient T-cell-mediated recognition in the treatment.
Summary
SymbolRARA
Nameretinoic acid receptor, alpha
Aliases NR1B1; RAR-alpha; nuclear receptor subfamily 1 group B member 1; nucleophosmin-retinoic acid receptor alpha ......
Chromosomal Location17q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RARA in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolRARA
Nameretinoic acid receptor, alpha
Aliases NR1B1; RAR-alpha; nuclear receptor subfamily 1 group B member 1; nucleophosmin-retinoic acid receptor alpha ......
Chromosomal Location17q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RARA in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.5290.176
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.480.817
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.5640.714
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2450.484
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.560.776
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1590.952
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2370.496
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2590.847
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1650.915
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3090.832
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7040.737
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2890.00017
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RARA in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolRARA
Nameretinoic acid receptor, alpha
Aliases NR1B1; RAR-alpha; nuclear receptor subfamily 1 group B member 1; nucleophosmin-retinoic acid receptor alpha ......
Chromosomal Location17q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RARA. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRARA
Nameretinoic acid receptor, alpha
Aliases NR1B1; RAR-alpha; nuclear receptor subfamily 1 group B member 1; nucleophosmin-retinoic acid receptor alpha ......
Chromosomal Location17q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RARA. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RARA.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRARA
Nameretinoic acid receptor, alpha
Aliases NR1B1; RAR-alpha; nuclear receptor subfamily 1 group B member 1; nucleophosmin-retinoic acid receptor alpha ......
Chromosomal Location17q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RARA. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRARA
Nameretinoic acid receptor, alpha
Aliases NR1B1; RAR-alpha; nuclear receptor subfamily 1 group B member 1; nucleophosmin-retinoic acid receptor alpha ......
Chromosomal Location17q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RARA expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRARA
Nameretinoic acid receptor, alpha
Aliases NR1B1; RAR-alpha; nuclear receptor subfamily 1 group B member 1; nucleophosmin-retinoic acid receptor alpha ......
Chromosomal Location17q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RARA and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRARA
Nameretinoic acid receptor, alpha
Aliases NR1B1; RAR-alpha; nuclear receptor subfamily 1 group B member 1; nucleophosmin-retinoic acid receptor alpha ......
Chromosomal Location17q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RARA collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting RARA.
ID Name Drug Type Targets #Targets
DB00210AdapaleneSmall MoleculeRARA, RARB, RARG, RXRA, RXRB, RXRG6
DB00459AcitretinSmall MoleculeRARA, RARB, RARG, RBP1, RXRA, RXRB, RXRG7
DB00523AlitretinoinSmall MoleculeCYP26C1, IGFBP3, PSG5, RARA, RARB, RARG, RXRA, RXRB, RXRG9
DB00755TretinoinSmall MoleculeALDH1A1, ALDH1A2, CYP26A1, CYP26B1, CYP26C1, GPRC5A, HPGDS, LCN1, ......19
DB00799TazaroteneSmall MoleculeRARA, RARB, RARG, RXRB4
DB00926EtretinateSmall MoleculeRARA, RARB, RARG, RXRA, RXRB, RXRG6
DB00982IsotretinoinSmall MoleculeRARA1
DB04942TamibaroteneSmall MoleculeRARA, RARB2
DB05785LGD-1550Small MoleculeJUN, RARA, RARB, RARG4